Fritsch, R., Andre, T., Bekaii-Saab, T., Cercek, A., Nakamura, Y., Raghav, K., … Tabernero, J. (2023). Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In SWISS MEDICAL WEEKLY (Vol. 153, pp. 70S-70S).

Fritsch, R., T. Andre, T. Bekaii-Saab, A. Cercek, Y. Nakamura, K. Raghav, S. Siena, et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” In SWISS MEDICAL WEEKLY, 153:70S-70S, 2023.

Fritsch R, Andre T, Bekaii-Saab T, Cercek A, Nakamura Y, Raghav K, et al. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In: SWISS MEDICAL WEEKLY. 2023. p. 70S-70S.

Fritsch, R., et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” SWISS MEDICAL WEEKLY, vol. 153, 2023, pp. 70S-70S.

Fritsch R, Andre T, Bekaii-Saab T, Cercek A, Nakamura Y, Raghav K, Siena S, Strickler J, Van Cutsem E, Adelberg D, Ramos J, Yang S, Yoshino T, Tabernero J. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). SWISS MEDICAL WEEKLY. 2023. p. 70S-70S.